SML2034

AGN 193109

≥98% (HPLC), pan-retinoic acid receptor (RAR) antagonist, powder

• Synonim(y): 4-[2-[5,6-Dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl]ethynyl]-benzoic acid, AGN193109, CD 3106
• Wzór empiryczny (zapis Hilla): C₂₈H₂₄O₂
• Numer CAS: 171746-21-7
• Masa cząsteczkowa: 392.49
• NACRES: NA.77
• UNSPSC Code: 12352200
• MDL number: MFCD00943817
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• Nazwa produktu: AGN 193109, ≥98% (HPLC)
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear (warmed)
• storage temp.: −20°C
• SMILES string: O=C(O)C1=CC=C(C#CC2=CC=C3C(C)(C)CC=C(C4=CC=C(C)C=C4)C3=C2)C=C1
• InChI: 1S/C28H24O2/c1-19-4-11-22(12-5-19)24-16-17-28(2,3)26-15-10-21(18-25(24)26)7-6-20-8-13-23(14-9-20)27(29)30/h4-5,8-16,18H,17H2,1-3H3,(H,29,30)
• InChI key: NCEQLLNVRRTCKJ-UHFFFAOYSA-N

Opis

Biochem/physiol Actions

AGN 193109 is an orally active retinoic acid receptor (RAR) antagonist that targets all three RAR subtypes with higher affinity (RARα/β/γ Kd = 2 nM) than all-trans retinoic acid/ATRA (RARα/β/γ Kd = 9/12/19 nM). AGN 193109 potently antagonizes against ATRA-induced transcription in RARα, RARβ, and RARγ transfected CV-1 cells (by 85%, 62%, and 100%, respectively, by equal molar AGN 193109 against ATRA). AGN 193109 is also widely employeed to block RAR-mediated physiological and pathalogical processes in mice and rats in vivo via oral (1-10 mg/kg) or topical (0.3-36 μmol/kg) administration.

High-affinity orally active pan-retinoic acid receptor (RAR) antagonist with in vitro and in vivo efficacy.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• Co się dzieje?: WGK 3
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable